SESSION 7: AGGRESSIVE EXTRANODAL ENTITIES

NONINVASIVE DETECTION, CLASSIFICATION, AND RISK STRATIFICATION OF PRIMARY CNS LYMPHOMAS BY CTDNA PROFILING abstract

J. A. Mutter, S. Alig, E. M. Lauer, M. S. Esfahani, et al.

The study authors demonstrate a robust and ultrasensitive detection of ctDNA at various disease milestones in PCNSL. Their findings suggest that ctDNA could serve as a valuable clinical biomarker for tumor burden assessment, outcome prediction, and biopsy-free lymphoma classification. They envision an important future role of ctDNA for personalized risk stratification and guiding therapies in clinical trials and in routine PCNSL management.

 

MATRIX INDUCTION FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT OR WHOLE-BRAIN IRRADIATION IN PRIMARY CNS LYMPHOMA. 7-YEAR RESULTS OF THE IELSG32 RANDOMIZED TRIAL. abstract

J. A. Mutter, S. Alig, E. M. Lauer, M. S. Esfahani, et al.

The study authors conclude that MATRix regimen was associated with an excellent long-term outcome. WBRT and ASCT had comparable efficacy. MATRix and ASCT did not result in higher non-relapse mortality or second tumors incidence in comparison to the other study arms, whereas WBRT led to impairment of specific cognitive functions.

 

INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA: 5-YEAR RESULTS OF THE IELSG30 TRIAL. abstract

A. Conconi, A. Chiappella, L. Orsucci, G. Gaidano, et al.

The study authors conclude that definitive assessment of the primary endpoint will need longer follow-up. Thus far, comparison of these results with those of the IELSG10 trial (5-yr PFS, 88 vs 74%; 5-yr OS, 92 vs 85%; 5-yr CNS relapse rate, 0 vs 6%) suggests that combined treatment of PTL with R-CHOP21 plus intensive CNS prophylaxis and loco-regional RT is feasible, may abrogate CNS relapses and lead to very promising outcomes. However, they note that late relapses, mainly at extranodal sites, still represent a clinical challenge.

 
 

IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL abstract

M. Martelli, E. Zucca, B. Botto, I. Kryachok, et al.

The study authors conclude that Initial regimen may have a critical impact on PMBCL outcome. R-CHOP21 appeared inferior to dose-dense/dose-intensive regimens.

 

OUTCOMES AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY abstract

V. Camus, C. Rossi, P. Sesques, J. Lequesne, et al.

The study authors conclude that PMBL patients treated with dose-dense immunochemotherapy without radiotherapy have excellent outcomes. They note that R-ACVBP acute toxicity was higher than that of R-CHOP14. Their data confirmed the prognostic importance of the baseline TMTV.

 

NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EXTENDED FOLLOW-UP FROM THE PHASE 2 CHECKMATE 436 STUDY abstract

P. L. Zinzani, A. Santoro, G. Gritti, P. Brice, et al.

The study authors conclude that in their extended FU of CheckMate 436, NIVO + BV demonstrated durable responses and long-term survival benefits; 4 patients remained progression-free without consolidation after NIVO + BV. Safety was consistent with prior findings. They conclude that their results further support NIVO + BV as a treatment option for patients with R/R PMBL.